ABCSG 30/BETH Summary

Multicenter, phase III, randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab.

Start: 09/2008
Coordinating investigator: Steger, G√ľnther; Vienna
Sample size: 3.500
(Click to enlarge)
ABCSG-30 Design

Link for studyteam-members only

Further information about this trial

Access to these informations only with keyword. If required, please ask the responsible project manager.